


Identifying Your Risk for Hereditary Breast and Ovarian Cancer

Sydney Brehany, MD
Rocky Mountain Cancer Centers
720-673-8238

Breanna Roscow, MS CGC
Myriad Genetics

You may have seen....



FEDERAL DISTRICT COURT
CENTRAL DIVISION
MDL Case No. 2:14-md-02510
Case No. 2:13-cv-00646-RJS
MEMORANDUM DECISION AND
ORDER DENYING PLAINTIFFS'
MOTION FOR PRELIMINARY
INJUNCTION
Judge Robert J. Shelby

THIS DOCUMENT RELATES TO:
UNIVERSITY OF UTAH RESEARCH
FOUNDATION, et al.
Plaintiffs,
v.
MYRIAD GENETICS CORPORATION,
et al.
Defendants.
On June 13, 2013, the Supreme Court issued a unanimous decision holding that "genes
of information they encode are not patent eligible simply because they have been isolated
to surrounding genetic material." Association for Molecular Pathology v. Myriad
Genetics Corp., 133 S. Ct. 2007, 2120 (2013). This case arises in the aftermath of that

TREATMENTS
Women With Breast Cancer Miss Out On Recommended Genetic Testing

February 7, 2017 - 12:03 PM ET
JESSICA BOODY

www.npr.org
Women With Breast Cancer Miss Out On Genetic Testing : Shots - Health News : NPR



Tests for mutations in BRCA genes that increase the risk of ovarian and breast cancer can help guide treatment and prevention.
Douglas C. Piza/AP

Women with breast cancer who are at high risk for having a BRCA mutation that raises cancer risk often don't get genetic testing, or even a chance to speak with a genetic counselor who'd help them weigh the necessity of such a test, a study finds.



...or have even been curious...

INVITAE INVITAE DIAGNOSTIC TESTING RESULTS

Patient name: John Doe
DOB: 1/1/1980
Sex: Male
MRN: 123456789

Sample type: Blood
Sample collection date: 1/15/2024
Sample accession date: 1/16/2024

Report date: 1/18/2024
Order #: 123456789
Clinical team: Dr. Smith

Reason for testing: Diagnostic test for a personal and family history of disease.

Test performed: Sequences entire and/or copy number testing of the BR genes listed in the results section below.
Includes Multi-Cancer Panel.

RESULT: POSITIVE

One Pathogenic variant identified in BRCA2. BRCA2 is associated with autosomal dominant hereditary breast and ovarian cancer syndrome and autosomal recessive Fanconi anemia. Additional Variant(s) of Uncertain Significance Identified.

GENE	BIOMAT	ZYGOSE	BIOMAT CLASSIFICATION
BRCA2	c.10002G>A (p.Glu3332Lys)	heterozygous	PATHOGENIC
BRCA2	c.11574C>G (p.Gln3858Arg)	heterozygous	Uncertain Significance

About this test: This diagnostic test evaluates BR genes for variants (genetic changes) that are associated with genetic disorders. Diagnostic genetic testing, when combined with family history and other medical results, may provide information to help individual risk, support a clinical diagnosis, and assist with the development of a personalized treatment and management strategy.



Genetic Ethnicity

West African: 76%
British Isles: 11%
Eastern European: 8%
Uncertain: 5%

Genetic Health


Type 2 Diabetes
Your genetics are associated with a typical likelihood.

Muscle Composition
Your genetic composition is common in elite power athletes.

ACTN3 gene
rs2230717

Based on your DNA results

37%



Excerpt: RiskScore® Results

Breast Cancer RiskScore®

35.3%

Remaining Lifetime Breast Cancer Risk (Age-Adjusted)

11.1% (Population) vs 35.3% (Your Risk)

Excerpt: MyRisk™ Management Tool

GENETIC RESULT NEGATIVE - NO CLINICALLY SIGNIFICANT VARIANTS IDENTIFIED

BREAST CANCER RISK SCORE™ REMAINING LIFETIME RISK 11.1%

Clinical History Analysis: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED

23andMe

Your 23andMe Results are Ready!

Dear Winslow,

Your 23andMe results are now available!


Log in now to view your results and start personalizing your 23andMe experience:

[view my results](#)


Sincerely,
The 23andMe Team

...but what does hereditary cancer really mean?

- All cancer is genetic, but not all cancer is hereditary.
- Cancer is caused by the abnormal growth of cells.
 - Abnormal growth can start when naturally occurring DNA damage builds up.



A gene is made up of DNA.
It carries instructions to make proteins.



The **proteins** have specific jobs that help your body work normally.

Normal gene



Healthy protein


Mutated gene



Damaged protein

- Genetic variation is normal
 - Everyone is unique and no two people are the same.
 - Slight differences in the DNA code from person to person is what causes the variation we see in the human population.
- Mutations are typically harmful
 - Genetic changes that inhibit normal cell function.
 - Can be responsible for causing a disease.

- Hereditary cancer is caused when a gene mutation is passed down through a family.
 - Can be inherited from either mother or father
- Only 5-10% of diagnosed cancers are considered hereditary.
- Familial cancer is when we see more cancer than we expect, but no gene mutation can be found on testing.



Identifying Hereditary Cancer

- Collect a family history
- Look for “red flags”
- Undergo genetic testing for genes known to cause hereditary cancer



Cancer at an early age

At an age younger than the average



Certain rare cancers

Such as ovarian, pancreatic, male breast cancer, sarcoma, etc.




Multiple cancers

Multiple individuals within the family may have cancer. Or, one individual may have multiple cancers

Identifying Hereditary Cancer

Why is it important to identify individuals with hereditary cancer?

Lifetime cancer risk for patients with hereditary cancer



Medical Management Options



Hereditary cancer risk



Familial cancer risk



General population cancer risk

Avoidance of risk factors

Increased surveillance

Risk-reducing agents

Risk-reducing surgery



- Can be for 1 gene or multiple genes at a time.
- Typically uses either a blood or saliva sample to collect DNA.
- Laboratories perform the sequencing and classify any variants found into different categories.

- Direct to Consumer (DTC) genetic testing has become more and more popular.
- DTC is testing not ordered by a health care provider.
- The sensitivity of DTC genetic testing is much lower than diagnostic testing.
 - Mutations can be missed!
 - Not all genes may be analyzed!
- FDA has issued a warning about DTC genetic tests:
 - “the test does not diagnose cancer or any other health conditions and should not be used to make medical decisions. **Results should be confirmed in a clinical setting before taking any medical action.**”

Genetic Testing Results



Negative

Negative for the genes tested.
Important to consider if there is a known mutation in your family.



VUS (Variant of Uncertain Significance)

Unknown at this time if change identified is harmful



Positive

Positive for a gene that increases the risk of cancer

Genetic Testing Results

Genetic testing results:



Implications:



Genetic Testing Costs / Legal Protections

- Testing guidelines are based on personal and/or family history of cancer.
- Testing is typically covered by insurance for those who meet guidelines.
- Cost of testing has decreased tremendously.
- GINA is a federal law that prohibits discrimination based on genetic testing.
- Some states have additional protections.
 - CO has protections for long- and short-term disability insurance



GINA **protects** most patients from **discrimination with health insurance or an employer**. Active-duty military personnel are an exception.




However, it does **NOT** protect a patient from discrimination with **life insurance or disability insurance**.


- US General population risk 12.4% (1 in 8 women)
- Approximately 264,000 women and 2,400 men are diagnosed each year
- Over 3.8 million breast cancer survivors living in the US in 2020
- Average 5-year survival is 90.8%, black women have the highest death rate from breast cancer
- Average age of diagnosis is 63 for White women & age 60 for Black women
- Approximately 12-14% of all breast cancers diagnosed are due to a hereditary cause

Diagnosing Breast Cancer


- Physical Exam:
 - Self-exam or clinical exam
 - Lump/mass or pain/swelling in breast or axilla
 - Asymmetry, skin or nipple changes
- Imaging:
 - Mammogram
 - Ultrasound
 - Breast MRI
- Biopsy:
 - Tissue is sent to pathology to confirm diagnosis
 - Ductal carcinoma in-situ
 - Invasive ductal/lobular



Spectrum of Breast Cancer Risk



Genes Linked to Hereditary Breast Cancer



Elevated risk of breast cancer but no defined number available


NTHL1 biallelic
RAD51C
RAD51D

*Data include risk to age 80


- Female US general population risk 1.1%
- 236,511 ovarian cancer survivors living in the US in 2020
- Average 5-year survival is 50.8%, lower for Black women
- Average age of diagnosis is 63
- Approximately 1 out of 4 (24%) of all ovarian cancers diagnosed are due to a hereditary cause

- Symptoms:
 - Bloating
 - Trouble eating or feeling full quickly
 - Fatigue
 - Bleeding or discharge from the vagina that is not normal for you
 - Pain or pressure in the pelvic area
 - Abdominal or back pain
 - A change in bathroom habits, such as more frequent or urgent need to urinate
- Symptoms may be difficult to distinguish from normal menstrual symptoms, and some women may not experience any symptoms at all.
- Difficult to detect early because there may not be symptoms unless the disease has spread.
- If diagnosed early, about 94% of patients live longer than 5 years after diagnosis.

Genes Linked to Hereditary Ovarian Cancer



BRCA1/BRCA2 Cancer Risks



*Based on sex assigned at birth


**Data include risk to age 80

BRCA1/BRCA2 Cancer Risks

	<i>BRCA1</i>	<i>BRCA2</i>
Female breast cancer* risk to age 50	28 - 51%	23 - 35%
Second breast cancer within 5 years of first diagnosis	8.9% - 20%	3.9% - 12%
Ovarian cancer risk to age 50	8 - 23%	0.4 - 4%
Ovarian cancer risk within 10 years of breast cancer diagnosis	12.7%	6.8%

Cancer Risks for Men

- Hereditary breast cancer doesn't just affect women.
- Men can be at risk too!
 - Male breast cancer
 - Prostate cancer
 - Pancreatic cancer
 - Melanoma
 - Other cancers
- Men have the same risk to pass a mutation to their children.



- Female breast cancer surveillance:
 - Breast awareness starting at age 18
 - Clinical breast exam every 6-12 months starting at age 25
 - Annual breast MRI starting at age 25
 - Annual mammogram (in addition to breast MRI) starting at age 30
- Male breast cancer surveillance:
 - Breast self-exam training and education starting at age 35
 - Annual clinical breast exam starting at age 35
 - Consider annual mammogram starting at age 50 (BRCA2 carriers)
- Management can be customized based on the age of cancer onset in the family.

Surgical Options for Breast Cancer Risk Reduction

Initial dx	2 nd breast cancer risk	Ovarian cancer risk	Management recommended	Management benefits
Localized Sporadic Breast cancer	2% after 5 years ⁹ Up to 11% by age 70	<1% 10 years after breast cancer dx ¹¹	Lumpectomy with radiation ¹⁰	Risk reduction from lumpectomy with radiation ¹⁰
VS				
Localized Hereditary Breast cancer	20% after 5 years ¹ Up to 64% by age 70 ²	Up to 13% 10 years after breast cancer dx ³ Up to 35% 20 years after breast cancer dx ³	Bilateral mastectomy Prophylactic BSO Chemoprevention ⁴	Mastectomy reduces breast cancer risk as much as 90% ⁵ Reduces the risk of contralateral breast cancer by as much as 53% ⁶ Oophorectomy reduces 2 nd breast cancer risk as much as 68% ⁷ Oophorectomy reduces ovarian cancer risk as much as 96% ⁸

Selective Estrogen Receptor Modulators (SERMs)

- Tamoxifen 20 mg/d (>35 yo)
- Raloxifene 60 mg/d (post-menopausal)

Aromatase Inhibitors*

(AIs; post-menopausal)

- Exemestane 25 mg/d
- Anastrozole 1 mg/d



Risk-Reducing Agent

~50% Risk Reduction (ER+)

FOR 5+ YEARS


- Screening tests that have been studied
 - Pelvic Exam
 - Transvaginal Ultrasound
 - CA-125 assay
- Concerns with these methods
 - Finding ovarian cancer by the methods above may not improve health
 - False-negative tests can occur
 - False-positives tests can occur
- Transvaginal ultrasound combined with CA-125 could be considered for BRCA1/2 carriers, although benefit is uncertain

Ovarian Cancer Risk-Reducing Agents

- If childbearing not completed


ORAL CONTRACEPTIVE PILLS

- Combined Estrogen and Progestin



50%
Risk Reduction
for 5+ Years


Risk Reduction Benefits




1. Hartmann LC, et al. *Proc Am Assoc Ca Res* 2000
2. Gronwald, et al. *Int J Cancer* 2006
3. Kauff ND, et al. *N Engl J Med* 2002
4. Rebbeck TR, et al. *N Engl J Med* 2002

- Individuals with a diagnosis of breast or ovarian cancer and a known BRCA mutation may benefit from targeted therapies.
 - PARP inhibitors target the defect in cell division resulting from BRCA mutations
 - Available as treatment for both breast and ovarian cancers


How Do PARP-inhibitors Work?




How Do PARP-inhibitors Work?



How Do PARP-inhibitors Work?




OlympiA Trial Localized Breast Cancer



(Tutt ANJ, et al. 2021)

SOLO1 Trial Advanced Ovarian Cancer



(Moore K, et al. 2018)

Seeking Care

- If you're concerned about possibly having hereditary cancer in your family, what should you do?
 - Speak to your doctor
 - Ask if a referral is right for you
 - Collect your family history information



- Document **as many relatives as you are able to**
 - First-degree = parents, siblings, children
 - Second-degree = aunts, uncles, grandparents
 - Third-degree = cousins, great-aunts, great-uncles
- Make note of **current age** or **age at death** for each relative
- List **ANY cancers and/or tumors** and what age they were diagnosed
 - Colon polyps and benign tumors count!
- Ask if a cancer was **metastatic** and/or what the primary cancer was
 - Note: brain, bone, liver and lung are common sites of metastases

Ask whether family members have ever had genetic testing and if so whether you can have a copy of their results

- Example Family History:
 - Mother, alive at age 65, diagnosed with breast cancer at age 60.
 - Maternal aunt, died at age 72, colon polyps x5, all after age 50.
 - Paternal grandmother, died at age 80, diagnosed with uterine cancer at age 55.
 - Sister, alive at age 38, skin cancer diagnosed at age 38.
 - Paternal uncle, alive at age 60, diagnosed with prostate cancer at age 58, metastasized to liver.
 - Maternal aunt, died at age 63, diagnosed with lung cancer at age 62, 20 year + history of tobacco use.

Thank you!

Identifying Your Risk for Hereditary Breast and Ovarian Cancer

Sydney Brehany, MD
Rocky Mountain Cancer Centers
720-673-8238

Breanna Roscow, MS CGC
Myriad Genetics